Clinical trials · Tennessee
High Grade Serous Ovarian Cancer clinical trials in Tennessee
We’re tracking 23 recruiting high grade serous ovarian cancer studies with a site in Tennessee — including Phase 1, Phase 1/Phase 2, Phase 2 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies in Tennessee
- NCT07318558RecruitingPhase 3
Study of Sac-TMT for advanced ovarian cancer without HRD
This trial is testing a new drug called Sac-TMT for people with advanced ovarian cancer that has not responded well to initial platinum-based chemotherapy and does not have a specific gene change called HRD. It aims to see if this drug can work better than standard treatment.
Germantown, TennesseeAges 18 years+ - NCT07059845RecruitingPhase 2
Studying mirvetuximab combos for ovarian cancer
This trial tests multiple combinations of the drug mirvetuximab soravtansine with other treatments for people with ovarian cancer. It aims to see how well these combos work and what side effects they cause.
Knoxville, TennesseeAges 18 years+ - NCT06799065RecruitingPhase 1
Testing a new drug for advanced solid tumors
This trial tests ATX-295, a daily pill that blocks a protein called KIF18A, in people with advanced solid tumors, including ovarian cancer. It is for those whose cancer has grown after standard treatments or who cannot have standard therapy.
Nashville, TennesseeAges 18 years+ - NCT06580314RecruitingPhase 3
Olaparib with or without bevacizumab for ovarian cancer
This trial tests whether taking the drug olaparib for one or two years, alone or with another drug called bevacizumab, can help keep ovarian cancer from coming back after initial chemotherapy and surgery. It is for people with certain genetic markers in their tumor.
Franklin, TennesseeAges 18 years+ - NCT06188520RecruitingPhase 1/Phase 2
Study of a new drug for advanced solid tumors in women
This trial tests a new drug, AZD8421, alone or with other treatments, for women with advanced solid tumors that have not responded to prior therapies. It aims to find a safe dose and see if it can help shrink or control the cancer.
Nashville, TennesseeAges 18 years+ - NCT04633239RecruitingPhase 1
Testing abemaciclib plus olaparib for recurrent ovarian cancer
This Phase 1 trial studies whether adding abemaciclib to olaparib can treat women with recurrent platinum-resistant ovarian cancer. It aims to find a safe dose and see how well the combination can control the cancer.
Nashville, TennesseeAges 18 years+ - NCT04657068RecruitingPhase 1/Phase 2
Study of ART0380 for advanced solid tumors
This study tests a new drug called ART0380 for people with advanced solid tumors that have not responded to standard treatments. It may be especially helpful for those with certain DNA repair gene changes (like ATM or BRCA). The drug will be given alone or with chemotherapy (gemcitabine or irinotecan) depending on the part of the trial.
Chattanooga, TennesseeAges 18 years+ - NCT04516447RecruitingPhase 1
Testing a new drug for advanced ovarian cancer
This Phase 1 trial studies how well and how safely azenosertib (ZN-c3) works in people with advanced ovarian, fallopian tube, or peritoneal cancer. It may help by offering a new treatment option for cancers that don’t respond well to platinum chemotherapy (platinum-resistant).
Nashville, TennesseeAges 18 years+ - NCT05579366RecruitingPhase 1/Phase 2
Study drug for advanced ovarian and other solid cancers
This Phase 1/2 trial studies Rinatabart Sesutecan to treat advanced cancers, with special focus on certain ovarian cancer types. It’s meant for people whose cancer has come back or has not responded to prior treatments.
Nashville, TennesseeAges 18 years+ - NCT05659381RecruitingPhase 3
Heated belly chemo plus niraparib after interval surgery for ovarian cancer
This Phase 3 study tests whether heated chemotherapy placed inside the belly, followed by interval surgery and the maintenance medicine niraparib, can improve outcomes for certain advanced ovarian, fallopian tube, or primary peritoneal cancers. It focuses on people whose tumors are HRD/LOH positive and who can have all visible disease removed.
Nashville, TennesseeAges 18 years+ - NCT05281471RecruitingPhase 3
Tested drug for platinum-resistant ovarian cancer with bevacizumab
This Phase 3 trial tests a treatment made of an investigational gene-based drug plus standard “platinum” chemotherapy and bevacizumab, compared with standard chemotherapy and bevacizumab. It’s for ovarian/fallopian tube/primary peritoneal cancers that have not responded to platinum chemotherapy or came back quickly.
Chattanooga, TennesseeAges 18 years+ - NCT06586957RecruitingPhase 1
Study of NKT3964 for advanced solid tumors
This trial is testing an experimental oral drug called NKT3964 for people with advanced solid tumors that have stopped responding to standard treatments. The drug works by blocking a protein called CDK2, which some cancers need to grow.
Nashville, TennesseeAges 18 years+ - NCT06915025RecruitingPhase 3
Study of a new drug for advanced ovarian cancer
This trial tests a new drug called IMNN-001 combined with standard chemotherapy for women with advanced ovarian, fallopian tube, or peritoneal cancer. The goal is to see if adding this drug can improve safety and effectiveness.
Chattanooga, TennesseeAges 18 years+ - NCT06930755RecruitingPhase 1
Study of an oral drug for recurrent ovarian cancer
This study tests a new oral drug called NMS-03305293 for women with recurrent ovarian cancer. It may work by targeting a specific protein involved in cancer growth. You may be eligible if you have high-grade serous ovarian cancer, have had limited prior treatments, and do not have a BRCA mutation.
Nashville, TennesseeAges 18 years+ - NCT07503808RecruitingPhase 1
IDE034 for advanced solid tumors with B7-H3 or PTK7
This study tests a new drug called IDE034 for people with advanced solid tumors that have certain markers (B7-H3 and PTK7). The drug may help by targeting these markers on cancer cells, and the study checks if it is safe and effective.
Nashville, TennesseeAges 18 years+ - NCT06172478RecruitingPhase 2
HER3-DXd for advanced solid tumors after prior treatment
This trial tests a new targeted drug called HER3-DXd for people with several types of advanced solid tumors that have stopped responding to standard treatments. The drug is an antibody-drug conjugate, designed to deliver chemotherapy directly to cancer cells that have a protein called HER3 on their surface.
Nashville, TennesseeAges 18 years+ - NCT07218809RecruitingPhase 3
Comparison of AZD5335 vs standard treatments for advanced ovarian cancer
This trial tests a new drug, AZD5335, against standard treatments (mirvetuximab soravtansine or chemotherapy) for women with platinum-resistant ovarian cancer. It aims to see if AZD5335 works better based on the level of a protein called FRα on your tumor cells.
Germantown, TennesseeAges 18 years+ - NCT06819007RecruitingPhase 3
Study of trastuzumab deruxtecan plus bevacizumab for HER2-positive ovarian cancer
This trial tests whether adding trastuzumab deruxtecan to standard maintenance therapy with bevacizumab works better than bevacizumab alone for people with advanced ovarian cancer that has the HER2 protein. It is for those who have finished initial chemotherapy plus bevacizumab and are now starting maintenance treatment.
Nashville, TennesseeAges 18 years+ - NCT07214779RecruitingPhase 3
New drug vs chemo for platinum-resistant ovarian cancer
This study tests a new drug (INCB123667) given as a pill, compared to standard chemotherapy, for people whose ovarian cancer has stopped responding to platinum-based treatments and whose tumor has high levels of a protein called Cyclin E1. The goal is to see if the new drug works better than standard chemo for this specific type of cancer.
Chattanooga, TennesseeAges 18 years+ - NCT07024784RecruitingPhase 2
Study of IMGN151 for gynecologic cancers
This study tests a new drug (IMGN151) given intravenously, alone or with other therapies, for people with certain gynecologic cancers, specifically high-grade serous ovarian, fallopian tube, or primary peritoneal cancer. The goal is to see how well it works and what side effects might occur.
Nashville, TennesseeAges 18 years+ - NCT07213804RecruitingPhase 3
Study of sofetabart mipitecan for ovarian cancer
This trial tests a new drug called sofetabart mipitecan for people with ovarian cancer that has come back after treatment. It is for those whose cancer is either resistant to platinum chemo (Part A) or sensitive to it (Parts B and C). The study will see if the drug can help shrink or slow the cancer.
Nashville, TennesseeAges 18 years+ - NCT06792552RecruitingPhase 1
Study of SIM0505 for advanced solid tumors
This trial tests a new drug called SIM0505 for people with advanced solid tumors that have not responded to standard treatments. The study looks at different cancer types, including ovarian cancer, kidney cancer, uterine cancer, and lung cancer, to see if SIM0505 can help shrink tumors or slow their growth.
Nashville, TennesseeAges 18 years+ - NCT04389632RecruitingPhase 1
Sigvotatug vedotin for advanced solid tumors that spread
This early-stage study tests a drug called sigvotatug vedotin in people with advanced solid cancers that cannot be removed or have spread. It aims to see how well the treatment works and what side effects it causes.
Nashville, TennesseeAges 18 years+
High Grade Serous Ovarian Cancer trials by city in Tennessee
Where these studies are running in Tennessee
Institutions with a site for the recruiting high grade serous ovarian cancer studies listed above.
- SCRI Oncology Partners · 7 studies
- Vanderbilt University Medical Center · 5 studies
- Erlanger Health System · 3 studies
- Research Site · 2 studies
- Sarah Cannon Research Institute · 2 studies
- Tennessee Oncology · 2 studies
- University of Tennessee Medical Center · 2 studies
- Baptist Memorial Hospital and Cancer Center-Memphis
What taking part in a high grade serous ovarian cancer study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
High Grade Serous Ovarian Cancer trials in other states
Common questions
- Are there high grade serous ovarian cancer clinical trials in Tennessee?
- Yes. We're currently tracking 23 recruiting high grade serous ovarian cancer studies with a site in Tennessee, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a high grade serous ovarian cancer study in Tennessee?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Tennessee to take part?
- Not necessarily. These studies have a site in Tennessee, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a high grade serous ovarian cancer trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New high grade serous ovarian cancer studies open in Tennessee regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.